Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Santini, Valeria, Almeida, Antonio, Giagounidis, Aristoteles, Gröpper, Stefanie, Jonasova, Anna, Vey, Norbert, Mufti, Ghulam J., Buckstein, Rena, Mittelman, Moshe, Platzbecker, Uwe, Shpilberg, Ofer, Ram, Ron, del Cañizo, Consuelo, Gattermann, Norbert, Ozawa, Keiya, Risueño, Alberto, MacBeth, Kyle J., Zhong, Jianhua, Séguy, Francis, Hoenekopp, Albert, Beach, C.L., Fenaux, Pierre·2016·Journal of Clinical Oncology

Abstract

Purpose: This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion–dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Patients and Methods: In total, 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The primary end point was the rate of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 weeks, duration of RBC-TI, erythroid response, health-related quality of life (HRQoL), and safety. Results: RBC-TI ≥ 8 weeks was achieved in 26.9% and 2.5% of patients in the lenalidomide and placebo groups, respectively (P < .001). Ninety percent of patients achieving RBC-TI responded within 16 weeks of treatment. Median duration of RBC-TI with lenalidomide was 30.9 weeks (95% CI, 20.7 to 59.1). Transfusion reduction of ≥ 4 units packed RBCs, on the basis of a 112-day assessment, was 21.8% in the lenalidomide group and 0% in the placebo group. Higher response rates were observed in patients with lower baseline endogenous erythropoietin ≤ 500 mU/mL (34.0% v 15.5% for > 500 mU/mL). At week 12, mean changes in HRQoL scores from baseline did not differ significantly between treatment groups, which suggests that lenalidomide did not adversely affect HRQoL. Achievement of RBC-TI ≥ 8 weeks was associated with significant improvements in HRQoL (P < .01). The most common treatment-emergent adverse events were neutropenia and thrombocytopenia. Conclusion: Lenalidomide yields sustained RBC-TI in 26.9% of RBC transfusion–dependent patients with lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was associated with improved HRQoL. Treatment-emergent adverse event data were consistent with the known safety profile of lenalidomide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.66.0118

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 215

Metadata

Authors
Santini, V., Almeida, A., Giagounidis, A., Gröpper, S., Jonasova, A., Vey, N., Mufti, G. J., Buckstein, R., Mittelman, M., Platzbecker, U., Shpilberg, O., Ram, R., del Cañizo, C., Gattermann, N., Ozawa, K., Risueño, A., MacBeth, K. J., Zhong, J., Séguy, F., Hoenekopp, A., Beach, C. L., & Fenaux, P.
Venue
Journal of Clinical Oncology
Published
2016-09-01
Volume
34
Issue
25
Pages
2988-2996
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2463012969
Cited by
215
References
5
FWCI
22.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. https://app.cochat.ai/papers/10.1200/jco.2015.66.0118
The paper
Santini, V., Almeida, A., Giagounidis, A., Gröpper, S., Jonasova, A., Vey, N., Mufti, G. J., Buckstein, R., Mittelman, M., Platzbecker, U., Shpilberg, O., Ram, R., del Cañizo, C., Gattermann, N., Ozawa, K., Risueño, A., MacBeth, K. J., Zhong, J., Séguy, F., . . . Fenaux, P. (2016). Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.66.0118

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.